Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2017

View Archived Issues

Spring Bank announces latest results from phase II inarigivir study

Investigational mineralocorticoid receptor antagonist KBP-5074 evaluated in phase I trial

Seres Therapeutics announces collaboration to test its microbiome therapies in cancer patients

OncoArendi Therapeutics patents arginase inhibitors

Bayer discovers new vasopressin receptor antagonists

FDA approves Genentech's Gazyva in new indication

GlaxoSmithKline discloses novel EZH2 inhibitors

Shanghai De Novo Pharmatech has presented TLR8 agonists

Amgen presents novel apelin receptor agonists

Sutent now approved in U.S. as adjuvant treatment for adults at high risk of recurrent RCC

Bayer and PeptiDream establish drug discovery collaboration

Evelo Biosciences and Mayo Clinic enter monoclonal microbial collaboration

Deerfield Management and Johns Hopkins announce creation of Bluefield Innovations

NICE recommends routine funding for Ibrance and Kisqali in England

Bayer presents preclinical data on the cardiac effects of BAY-1142524 after myocardial infarction

bb-2121 receives FDA breakthrough therapy and EMA PRIME designations

NIH grant supports MRSA osteomyelitis research at University of Rochester

FDA first to approve Hemlibra for hemophilia A

Thetis Pharmaceuticals obtains NIH grant to support development of ulcerative colitis drug

Bayer reports first-in-human data for BR-6819

FDA issues alert regarding Takeda's febuxostat for gout

Alnylam Pharmaceuticals begins rolling NDA submission for patisiran

FDA approves new formulation and pediatric indication for Tekturna

PIN Pharma begins phase I study of immune-modulator in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...